AI Article Synopsis
- - A new controlled human infection model for schistosomiasis (CHI-S) using female-only Schistosoma mansoni cercariae was developed to improve vaccine research and understand early immune responses.
- - Thirteen healthy participants were exposed to either 10 or 20 female cercariae, resulting in most experiencing rash or mild symptoms, with some showing detectable infection despite receiving praziquantel treatment.
- - The study found that female infections display similar symptoms and immune responses as male infections but show greater resistance to praziquantel, suggesting challenges for future research and disease control efforts.
Article Abstract
Background: A controlled human infection model for schistosomiasis (CHI-S) can speed up vaccine development and provides insight into early immune responses following schistosome exposure. Recently, we established CHI-S model using single-sex male-only Schistosoma mansoni (Sm) cercariae in Schistosoma-naïve individuals. Given important differences in antigenic profile and human immune responses to schistosomes of different sex, we pioneered a single-sex female-only CHI-S model for future use in vaccine development.
Methods: We exposed 13 healthy, Schistosoma-naïve adult participants to 10 (n = 3) or 20 (n = 10) female cercariae and followed for 20 weeks, receiving treatment with praziquantel (PZQ) 60 mg/kg at week 8 and 12 after exposure.
Findings: The majority (11/13) participants reported rash and/or itch at the site of exposure, 5/13 had transient symptoms of acute schistosomiasis. Exposure to 20 cercariae led to detectable infection, defined as serum circulating anodic antigen levels >1.0 pg/mL, in 6/10 participants. Despite two rounds of PZQ treatment, 4/13 participants showed signs of persistent infection. Additional one- or three-day PZQ treatment (1 × 60 mg/kg and 3 × 60 mg/kg) or artemether did not result in cure, but over time three participants self-cured. Antibody, cellular, and cytokine responses peaked at week 4 post infection, with a mixed Th1, Th2, and regulatory profile. Cellular responses were (most) discriminative for symptoms.
Interpretation: Female-only infections exhibit similar clinical and immunological profiles as male-only infections but are more resistant to PZQ treatment. This limits future use of this model and may have important implications for disease control programs.
Funding: European Union's Horizon 2020 (grant no. 81564).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585222 | PMC |
| http://dx.doi.org/10.1016/j.ebiom.2023.104832 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Contextual factors influencing schistosomiasis treatment and identification of delivery platforms for arpraziquantel in hard-to-reach areas and populations in Homa Bay County, Kenya.
PLOS Glob Public Health
December 2024
Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
A new formulation of praziquantel, arpraziquantel (arPZQ), has been developed for preschool-aged children (PSAC) to fill the treatment gap for this age group in schistosomiasis control and elimination programs. There is now a priority to ensure that the drug reaches all at-risk PSAC in endemic areas, including hard-to-reach areas and populations. This study aimed to determine schistosomiasis treatment-related contextual factors among fishermen and island populations in Homa Bay County, Kenya, and to identify a suitable platform to deliver arPZQ.
View Article and Find Full Text PDFEfficacy and safety of praziquantel plus artemisinin-based combinations versus praziquantel in the treatment of Kenyan children with infection: open-label, randomized, head-to-head, non-inferiority trial.
Antimicrob Agents Chemother
December 2024
Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Praziquantel alone is insufficient for the control of schistosomiasis due to poor efficacy against juvenile worms and increasing concerns about the risk of drug resistance. We compared the efficacy and safety of praziquantel combined with four different artemisinin-based combinations to praziquantel alone in treating infection in Kenyan children. In this randomized, open-label, five-arm, head-to-head, non-inferiority trial, children (aged 9-15 years) with infection according to duplicate Kato Katz thick smears from a stool sample in the Mwea irrigation scheme of central Kenya, were enrolled.
View Article and Find Full Text PDFVirtual screening and molecular dynamics studies of novel small molecules targeting DHODH: identification of potential inhibitors.
In Silico Pharmacol
November 2024
Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, 600077 Tamil Nadu India.
Article Synopsis
- * A structure-based drug design approach was utilized to create eighteen new inhibitors targeting SmDHODH, with successful binding characteristics and improved efficacy compared to existing treatments.
- * The study highlights the significance of molecular properties in developing effective drugs for schistosomiasis, demonstrating the new compounds' strong inhibition of SmDHODH and promising pharmacokinetic profiles.
A study protocol for a multi-country cluster randomized controlled trial of the impact of a multi-component One Health strategy to eliminate Opisthorchis viverrini and soil transmitted helminths in the Lower Mekong Basin.
Trials
November 2024
QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Background: Opisthorchis viverrini (OV) and soil-transmitted helminths (STH) are two of the most common helminths contributing to the Neglected Tropical Disease (NTDs) burden in the Lower Mekong Basin. Although mass drug administration is the cornerstone of control programs to reduce morbidity caused by these infections, this approach has limitations in preventing re-infections. Elimination requires additional measures such as reservoir host treatment, improved hygiene and health education to reinforce MDA's impact.
View Article and Find Full Text PDFSchistosomiasis Chemotherapy, Chemoprevention, and Vaccines: History, Progress, and Priorities.
Immun Inflamm Dis
November 2024
Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, AlBeheira, Egypt.
Article Synopsis
- * The transmission of this disease requires freshwater snails and human contact with contaminated water, with no effective vaccines currently available despite ongoing research into potential candidates.
- * Praziquantel (PZQ) is a key medication for treating schistosomiasis, but its widespread use has raised concerns about drug resistance, while reinfection in high-risk areas and immature worms limit its effectiveness, highlighting the urgent need for a vaccine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!